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ABSTRACT
Objectives: To examine adherence to serum
creatinine and potassium monitoring and
discontinuation guidelines following initiation of
treatment with ACE inhibitors (ACEI) or angiotensin
receptor blockers (ARBs); and whether high-risk
patients are monitored.
Design: A general practice-based cohort study using
electronic health records from the UK Clinical Practice
Research Datalink and Hospital Episode Statistics.
Setting: UK primary care, 2004–2014.
Subjects: 223 814 new ACEI/ARB users.
Main outcome measures: Proportion of patients
with renal function monitoring before and after ACEI/
ARB initiation; creatinine increase ≥30% or potassium
levels >6 mmol/L at first follow-up monitoring; and
treatment discontinuation after such changes. Using
logistic regression models, we also examined patient
characteristics associated with these biochemical
changes, and with follow-up monitoring within the
guideline recommendation of 2 weeks after treatment
initiation.
Results: 10% of patients had neither baseline nor
follow-up monitoring of creatinine within 12 months
before and 2 months after initiation of an ACEI/ARB,
28% had monitoring only at baseline, 15% only at
follow-up, and 47% both at baseline and follow-up.
The median period between the most recent baseline
monitoring and drug initiation was 40 days (IQR
12–125 days). 34% of patients had baseline creatinine
monitoring within 1 month before initiating therapy,
but <10% also had the guideline-recommended follow-
up test recorded within 2 weeks. Among patients
experiencing a creatinine increase ≥30% (n=567,
1.2%) or potassium level >6 mmol/L (n=191, 0.4%),
80% continued treatment. Although patients with prior
myocardial infarction, hypertension or baseline
potassium >5 mmol/L were at high risk of ≥30%
increase in creatinine after ACEI/ARB initiation, there
was no evidence that they were more frequently
monitored.
Conclusions: Only one-tenth of patients initiating
ACEI/ARB therapy receive the guideline-recommended
creatinine monitoring. Moreover, the vast majority of
the patients fulfilling postinitiation discontinuation
criteria for creatinine and potassium increases continue
on treatment.
INTRODUCTION
Renin angiotensin system blockade using
ACE inhibitors (ACEI) and angiotensin
receptor blockers (ARBs) is a mainstay in
treatment of hypertension,1 heart failure,2
diabetic microalbuminuria or proteinuric
Strengths and limitations of this study
▪ This is the largest monitoring study until now,
examining both adherence to creatinine and
potassium monitoring and discontinuation
guidelines following initiation of ACE inhibitors
or angiotensin receptor blockers in UK primary
care, and whether patients are monitored in
accordance with their individual risk profile.
▪ Use of the UK Clinical Practice Research Datalink
and Hospital Episode Statistics ensured that the
study was population-based and not restricted to
specific demographic, hospital or insurance
groups.
▪ Blood tests performed in hospital systems were
not recorded in the Clinical Practice Research
Datalink, but the results were consistent for
patients with no recent hospital admissions.
▪ If the recording of creatinine levels was not
missing completely at random, the associations
between patient characteristics and creatinine
increase may have been underestimated.
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renal diseases,3 and after myocardial infarction.4
However, some patients experience a sudden decline in
kidney function when initiating these drugs, presumably
due to antagonism of the angiotensin II-mediated effer-
ent arteriolar constriction or impaired kidney excretion
of potassium.5 6
The potential impact on kidney function should be
evaluated by comparing preinitiation and postinitiation
levels of serum creatinine and potassium.7
Discontinuation is recommended if the rise in creatinine
exceeds 30% above baseline or if hyperkalaemia
develops.8 It is unclear whether these recommendations
are routinely followed in clinical practice.9
A few studies have compared baseline and follow-up
monitoring results,9 but large studies using contempor-
ary data with reference to current guidelines are lacking,
and it is unknown whether patients’ individual risk of
renal impairment inﬂuences their likelihood of being
monitored.9 We therefore examined adherence to cre-
atinine and potassium monitoring and treatment discon-
tinuation guidelines following ACEI/ARB initiation in
UK primary care, and whether patients are monitored in
accordance with their individual risk proﬁle.
METHODS
Data sources
We used the UK’s Clinical Practice Research Datalink
(CPRD) linked to hospital record data from the
Hospital Episode Statistics (HES) database. The CPRD
database contains primary care electronic health record
data from 7% of the UK population (∼15 million
patient lives, with ∼8 million currently under
follow-up).10 Patients included in the CPRD are largely
representative of the UK population in terms of age, sex
and ethnicity.10 11 Information recorded in the database
includes demographics such as sex and year of birth, the
location of the general practice, medical diagnoses
(based on ‘Read’ codes), drug prescriptions and a range
of routine laboratory test results. HES records cover all
hospital admissions for patients covered by the National
Health Service (NHS) who receive treatment either
from English NHS trusts or independent providers.10 11
Fifty-eight per cent of general practices included in the
CPRD have agreed to HES linkage.10 We obtained
linked data on socioeconomic status (index of multiple
deprivation) based on area of residence.
Monitoring guidelines
Consistent with other international guidelines, the
National Institute for Health and Care Excellence
(NICE) recommends baseline testing of creatinine when
initiating ACEI/ARB therapy in patients with hyperten-
sion,1 heart failure,2 myocardial infarction4 or chronic
kidney disease (CKD).3 The time interval for baseline
testing is not further speciﬁed.1–4 Among patients with
heart failure, myocardial infarction and CKD, NICE
recommends follow-up monitoring within 2 weeks of
treatment initiation,2–4 and for patients with myocardial
infarction at least annually thereafter.4 A baseline assess-
ment and follow-up test within 2 weeks is also recom-
mended by the UK Renal Association,12 as well as the
frequently used online web resource General Practice
(GP) Notebook.13 GP Notebook additionally recom-
mends monitoring 1, 3, 6 and 12 months after the ﬁrst
follow-up test.13 NICE recommends not to initiate
ACEI/ARBs in patients with a baseline potassium level
>5 mmol/L and to discontinue therapy if potassium
rises above 6 mmol/L.
ACEI/ARB initiators
We identiﬁed a cohort of all HES-linked CPRD patients
aged ≥18 years, who initiated ACEI/ARB treatment
between 1 January 2004 and 31 March 2014. We did not
include earlier calendar periods, as laboratory data
before 2004 were incomplete due to interface problems
between laboratory reporting software and GP practice
management software.14 Also, creatinine testing was
incentivised in 2004 with the introduction of the dia-
betes Quality and Outcomes Framework (QOF) and
further in 2006 with the CKD QOF.14 To rule out any
potential inﬂuence of incomplete data around 2004, we
also examined the most recent 5-year calendar period
separately in a sensitivity analysis. New users were
deﬁned as persons with at least 1 year of continuous
registration in the CPRD before their ﬁrst recorded
ACEI/ARB prescription.
Laboratory data
All creatinine test results were extracted from the
general practice records of the study population, using
creatinine-speciﬁc codes in CPRD. Cross-reference was
then made to creatinine test results identiﬁed from a
broad Read code search. Any irrelevant codes were
excluded. Renal function testing in the UK includes cre-
atinine and potassium, so it can be inferred that testing
frequency is similar to creatinine for potassium. When
we conducted analyses related to potassium levels, we
repeated the procedure used to identify creatinine levels
for potassium test results.
Patient characteristics
We obtained information for all patients on age, sex, cal-
endar period of ACEI/ARB initiation (2004–2008 and
2010–2014), socioeconomic status (quintiles of the 2004
index of multiple deprivation scores), lifestyle factors
(smoking, alcohol intake and body mass index), baseline
potassium level (≤5 or >5 mmol/L), CKD, cardiovascu-
lar comorbidities (heart failure, myocardial infarction,
hypertension, peripheral arterial disease and arrhyth-
mia) and diabetes.15 We used algorithms for smoking
status, alcohol intake and body mass index based on the
most recent records in the CPRD before ACEI/ARB ini-
tiation.16 17 As measures of baseline creatinine and
potassium levels, we used the single most recent meas-
urement within 12 months before the ﬁrst ACEI/ARB
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prescription. We calculated the estimated glomerular ﬁl-
tration rate (eGFR) level from the most recent creatin-
ine measurement and CKD stage from the CKD
Epidemiology Collaboration (CKD-EPI) equation.18
Cardiovascular comorbidities and diabetes were identi-
ﬁed from both the CPRD and HES based on diagnoses
recorded prior to ACEI/ARB initiation. The code lists
for all variables are provided in the online
supplementary appendix.
Patient involvement
The study included no patient involvement.
Statistical analysis
We described ACEI/ARB users according to patient
characteristics, both overall and according to creatinine
monitoring status (no baseline or follow-up monitoring,
baseline only, follow-up only, and both baseline and
follow-up monitoring). Baseline monitoring was deﬁned
as a test performed on the date of drug initiation or
within either 12 months before (wide interval) or
1 month before initiation (more ideal interval assumed
to be driven by planned ACEI/ARB initiation). To
accord with the postinitiation monitoring interval
recommended from previous trial data, we considered
only follow-up monitoring within the ﬁrst 2 months after
drug initiation.8
We calculated the proportion of persons in the total
cohort of new users who had baseline and follow-up
monitoring (within 1, 3 and 12 months before drug initi-
ation and within 2 weeks, 1 month and 2 months after
initiation). We then computed the proportion of
persons with both baseline and initial follow-up monitor-
ing within the guideline-recommended interval of
2 weeks following drug initiation.
We repeated the analyses for continuing users, in
order to examine adherence to the stricter guideline
recommendations for ongoing monitoring (ie, monitor-
ing within 1, 3, 6 and 12 months after the ﬁrst retest).13
Continuation was deﬁned as ACEI/ARB use beyond
30 days following the monitoring date, that is, when the
end date of the ﬁrst continuous course of therapy was
after the date of the ﬁrst monitoring date plus 30 days
(to allow for stockpiling). The end date of each pre-
scription was calculated by adding the prescription dur-
ation (total number of tablets prescribed divided by the
speciﬁed number of tablets per day) to the prescription
date. In identifying continuous courses of therapy, we
allowed for a 30-day gap between the end date of one
prescription and the start of the next consecutive
prescription.
In sensitivity analyses, we repeated the analyses (1)
extending the follow-up window for the ﬁrst follow-up
monitoring from 2 to 3 weeks to account for minor
delays; (2) including only the most recent calendar
period (2009–2014) to account for temporal changes in
data completeness and quality of care; (3) excluding
patients with a hospital admission or discharge date
within 1 month before or after their ﬁrst ACEI/ARB pre-
scription, in order to account for drug initiation and any
subsequent renal function tests occurring in the hospital
and therefore not captured in the CPRD; (4) focusing
on speciﬁc patient subgroups (heart failure, myocardial
infarction, hypertension, CKD (eGFR<60 mL/min/
1.73 m2), peripheral arterial disease and diabetes); and
(5) deﬁning drug use continuation as ACEI/ARB use
beyond 90 days (instead of 30 days) after the ﬁrst retest
date.
We used the subcohort of patients with both baseline
and follow-up monitoring to calculate the proportion of
patients with creatinine increases ≥30% or potassium
levels >6 mmol/L at the ﬁrst follow-up monitoring
within 2 months after initiation, as well as the proportion
of patients continuing treatment despite these contrain-
dications for use.
Finally, we ﬁtted a logistic regression model to identify
patient characteristics associated with a severe decline in
renal function (creatinine increase ≥30% or potassium
level >6 mmol/L) and compared these characteristics
with those associated with receiving postinitiation
follow-up monitoring within 2 weeks. The model
included age, sex, CKD stage, cardiovascular comorbid-
ities, diabetes and baseline potassium level (>5 vs
≤5 mmol/L). In three additional model-based sensitivity
analyses, we repeated the analyses (1) excluding patients
with a recent hospitalisation (as deﬁned above); (2)
omitting baseline potassium from the model to examine
the extent of potential overﬁtting when both baseline
potassium and CKD stage were kept in the model; and
(3) also adjusting additionally for ethnicity.
All analyses were performed using the STATA 14 statis-
tical software package.
RESULTS
Serum creatinine monitoring before and after
ACEI/ARB initiation
We identiﬁed 223 814 new users of ACEI/ARB. We com-
pared these patients in four groups: 21 411 (10%) had
no baseline or follow-up creatinine tests within
12 months before and 2 months after treatment initi-
ation, 63 359 (28%) had only a baseline test, 33 185
(15%) had only follow-up tests, and 105 859 (47%) had
both baseline and follow-up tests (table 1). Median age
varied only slightly between the groups (60, 62, 59 and
63 years, respectively) and there were no substantial dif-
ferences in socioeconomic status, lifestyle factors or per-
ipheral arterial disease. Compared with patients with
neither preinitiation nor postinitiation monitoring,
patients with both were more likely to have diagnosed
hypertension (76% vs 61%) and diabetes (20% vs 7%),
but less likely to have diagnosed heart failure (4% vs
7%), myocardial infarction (4% vs 18%) and arrhythmia
(7% vs 10%). Among patients with baseline monitoring,
83% did not have CKD, 13% stage 3a, 3% stage 3b,
0.5% stage 4 CKD. In the same population, 7% started
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ACEI/ARB therapy despite baseline potassium above
5 mmol/L. The median number of days between base-
line monitoring and ﬁrst prescription date was 40 days
(IQR 12–125 days).
Among all patients initiating ACEI/ARB therapy, the
proportion of patients receiving creatinine testing before
initiation was 76% within 12 months of treatment initi-
ation, declining to 34% within 1 month before initiation
Table 1 Characteristics of patients initiating ACE inhibitors or ARBs in the UK primary care during 2004–2014, by monitoring
groups
Serum creatinine monitoring*
Total
No baseline or
follow-up tests
Baseline test
only
Follow-up test
only
Baseline and
follow-up tests
Total number 21 411 (100) 63 359 (100) 33 185 (100) 105 859 (100) 223 814 (100)
Female sex 8882 (41) 27 722 (44) 14 570 (44) 49 109 (46) 100 283 (45)
Age (years)
<50 5019 (23) 13 697 (22) 8732 (26) 19 910 (19) 47 358 (21)
50–59 5485 (26) 15 135 (24) 9115 (27) 24 866 (23) 54 601 (24)
60–69 4863 (23) 15 586 (25) 7776 (23) 27 790 (26) 56 015 (25)
70–79 3579 (17) 12 193 (19) 5066 (15) 22 152 (21) 42 990 (19)
80+ 2465 (12) 6748 (11) 2496 (8) 11 141 (11) 22 850 (10)
Calendar period
2004–2008 14 814 (69) 40 667 (64) 19 808 (60) 60 902 (58) 136 191 (61)
2009–2014 6597 (31) 22 692 (36) 13 377 (40) 44 957 (42) 87 623 (39)
SES quintiles
1 (low) 5153 (24) 15 290 (24) 8533 (26) 25 577 (24) 54 553 (24)
2 4725 (22) 14 331 (23) 7887 (24) 24 851 (23) 51 794 (23)
3 4341 (20) 13 028 (21) 6890 (21) 22 629 (21) 46 888 (21)
4 4254 (20) 12 140 (19) 5931 (18) 19 318 (18) 41 643 (19)
5 (high) 2925 (14) 8508 (13) 3898 (12) 13 359 (13) 28 690 (13)
Missing 13 (0) 62 (0) 46 (0) 125 (0) 246 (0)
Smoking status
Never 7860 (37) 22 496 (36) 12 229 (37) 36 895 (35) 79 480 (36)
Ever 13 433 (63) 40 797 (64) 20 915 (63) 68 939 (65) 144 084 (64)
Missing 118 (1) 66 (0) 41 (0) 25 (0) 250 (0)
Alcohol intake
No use 2556 (12) 7819 (12) 3409 (10) 11 088 (10) 24 872 (11)
Current 15 495 (72) 47 322 (75) 25 656 (77) 82 870 (78) 171 343 (77)
Former 1328 (6) 4499 (7) 1933 (6) 7490 (7) 15 250 (7)
Missing 2032 (9) 3719 (6) 2187 (7) 4411 (4) 12 349 (6)
BMI groups
Underweight 282 (1) 700 (1) 304 (1) 1008 (1) 2294 (1)
Healthy weight 5666 (26) 15 406 (24) 8089 (24) 24 972 (24) 54 133 (24)
Overweight 7677 (36) 23 755 (37) 12 484 (38) 40 556 (38) 84 472 (38)
Obesity 6009 (28) 20 660 (33) 10 527 (32) 35 887 (34) 73 083 (33)
Missing 1777 (8) 2838 (4) 1781 (5) 3436 (3) 9832 (4)
CKD (eGFR)†
Stage ≤2 (≥60) 10 326 (48) 53 773 (85) 19 470 (59) 87 484 (83) 171 053 (76)
Stage 3a (45–59) 1137 (5) 7382 (12) 1766 (5) 13 913 (13) 24 198 (11)
Stage 3b (30–44) 217 (1) 1885 (3) 265 (1) 3854 (4) 6221 (3)
Stage 4 (15–29) 24 (0) 319 (1) 29 (0) 608 (1) 980 (0)
Not measured 9707 (45) 0 (0) 11 655 (35) 0 (0) 21 362 (10)
CV comorbidities‡
Heart failure 1568 (7) 3270 (5) 1386 (4) 4583 (4) 10 807 (5)
Myocardial infarction 3881 (18) 4653 (7) 3203 (10) 4620 (4) 16 357 (7)
Hypertension 13 023 (61) 44 273 (70) 24 195 (73) 80 946 (76) 162 437 (73)
Peripheral arterial disease 471 (2) 1590 (3) 523 (2) 2547 (2) 5131 (2)
Arrhythmia 2057 (10) 4973 (8) 2000 (6) 7123 (7) 16 153 (7)
Diabetes mellitus 1399 (7) 13 586 (21) 1992 (6) 21 548 (20) 38 525 (17)
*Monitoring groups based on baseline (within 12 months before) and follow-up (within 2 months after) serum creatinine monitoring.
†Calculated from most recent creatinine measurement within 12 months before the first prescription date.
‡Diagnosis ever registered before ACE/ARB initiation in CRPD or HES.
ARB, angiotensin receptor blocker; BMI, body mass index; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular
filtration rate; HES, Hospital Episode Statistics; SES, socioeconomic status.
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(table 2). The proportion with follow-up testing after
treatment initiation was 29% within 2 weeks, increasing
to 62% within 2 months. Among ACEI/ARB initiators
who had a baseline test within 12 months, 21% also had a
follow-up test within 2 weeks after starting treatment
(table 3). However, among patients undergoing testing
within 1 month prior to treatment initiation, only 9%
had also the recommended follow-up test within 2 weeks
of treatment start. When we extended the follow-up
window to 3 weeks, this proportion increased to only 14%
(table 3). Among patients continuing treatment, only 1%
had follow-up measurements at 1, 3, 6 and 12 months
after the ﬁrst retest, in compliance with the strictest rec-
ommendation (eTable 1). These results were unchanged
when the analysis was restricted to the most recent
calendar period (eTables 1–2) and to patients with heart
failure, myocardial infarction, hypertension, peripheral
arterial disease, diabetes or no recent hospitalisation
(eTable 3). Only patients with CKD received a slightly
higher degree of monitoring (13%) within 2 weeks fol-
lowing treatment initiation (eTable 3). The proportion
with follow-up testing after treatment initiation was also
unchanged when results were stratiﬁed by date of ACEI/
ARB initiation in 2-year intervals (eTable 4).
Serum creatinine and potassium changes after
ACEI/ARB initiation
Among patients receiving the recommended renal func-
tion monitoring, 567 (1.2%) experienced a creatinine
increase ≥30% and 191 (0.4%) a potassium level
>6 mmol/L at their ﬁrst follow-up test within 2 months
of treatment initiation (1.4% experienced the increase
in creatinine and/or potassium) (table 4). Among these
patients, 80% continued treatment beyond 30 days fol-
lowing the monitoring date (table 4). The sensitivity ana-
lysis showed that 65% of patients with a creatinine
increase ≥30% and 60% of those with a potassium level
>6 mmol/L also continued treatment beyond 90 days
after the monitoring date (eTable 5). The results
remained consistent for longer baseline monitoring
intervals (eTable 5).
Patients at high risk for creatinine increases ≥30%
When we examined patient characteristics associated
with a creatinine increase ≥30% and adjusted for the
Table 2 Prevalence of baseline and follow-up serum
creatinine monitoring among patients initiating ACE
inhibitors or angiotensin receptor blockers, 2004–2014
Serum creatinine, ≥1 test
Total number n=223 814 (100%)
Baseline testing
≤12 months before 169 218 (76%)
≤3 months before 115 348 (52%)
≤1 month before 75 476 (34%)
Follow-up testing
≤2 weeks after 65 090 (29%)
≤1 month after 114 244 (51%)
≤2 months after 139 044 (62%)
Table 3 Prevalence of baseline and follow-up serum creatinine monitoring among patients initiating ACE inhibitors or
angiotensin receptor blockers according to clinical guideline recommendations
Clinical guidelines
All initiators
n=223 814 (100%)
NICE
heart failure
NICE
MI
NICE/UKRA
hypertension
NICE
CKD
GP
Notebook
Wide baseline
interval
(≤12-months)
Ideal baseline
interval
(≤1 month)
Baseline testing x x x x x 169 218 (76%) 75 476 (34%)
+Follow-up test ≤2 weeks* x NA x x x 46 486 (21%) 19 679 (9%)
+Follow-up test ≤3 weeks† 70 792 (32%) 30 451 (14%)
*Follow-up test among those with baseline measurements.
†Sensitivity analysis illustrating the importance of 2-week vs 3-week cut-off interval in follow-up test intervals.
CKD, chronic kidney disease; GP, general practice; MI, myocardial infarction; NA, not applicable; NICE, National Institute for Health and Care
Excellence; UKRA, United Kingdom Renal Association.
Table 4 Proportion of new users of ACE inhibitors or angiotensin receptor blockers who continue or discontinue treatment
according to guideline recommended cut-off levels of serum creatinine and potassium at follow-up testing*
Continuation† Discontinuation† Total
Total number, % 42 942 (93.1) 3178 (6.9) 46 120 (100)
Serum creatinine increase ≥30%, n (%) 462 (81.5) 105 (18.5) 567 (100)
Serum potassium >6 mmol/L, n (%) 150 (78.5) 41 (21.5) 191 (100)
*Calculated from the most recent measurements within 1 month before and 2 months after drug initiation.
†A patient was considered a continuous user when the end date of the first continuous course of therapy was larger than the date of the first
follow-up monitoring +30 days (to allow for stockpiling and irregular use).
Schmidt M, et al. BMJ Open 2017;7:e012818. doi:10.1136/bmjopen-2016-012818 5
Open Access
Table 5 Association between patient characteristics and serum creatinine increase ≥30% and follow-up monitoring within 2 weeks following initiation of ACE inhibitors or
angiotensin receptor blockers
OR (95% CIs)
Characteristics
Serum creatinine monitoring ≤2 weeks Serum creatinine increase ≥30%* Serum potassium increase ≥30%*
Age-adjusted and
sex-adjusted Fully adjusted†
Age-adjusted and
sex-adjusted Fully adjusted†
Age-adjusted and
sex-adjusted Fully adjusted†
Female sex 1.07 (1.04 to 1.10) 1.07 (1.04 to 1.09) 1.39 (1.26 to 1.53) 1.63 (1.47 to 1.80) 0.87 (0.66 to 1.16) 0.94 (0.70 to 1.26)
Age (years)
<50 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
50–59 0.98 (0.94 to 1.01) 0.98 (0.95 to 1.02) 0.88 (0.74 to 1.05) 0.86 (0.72 to 1.03) 1.29 (0.79 to 2.11) 1.10 (0.67 to 1.81)
60–69 1.05 (1.02 to 1.09) 1.05 (1.01 to 1.09) 1.03 (0.88 to 1.21) 1.00 (0.85 to 1.19) 1.35 (0.84 to 2.17) 0.97 (0.60 to 1.58)
70–79 1.18 (1.14 to 1.23) 1.18 (1.13 to 1.23) 1.49 (1.27 to 1.74) 1.36 (1.15 to 1.61) 1.65 (1.02 to 2.66) 0.74 (0.43 to 1.26)
80+ 1.20 (1.14 to 1.25) 1.17 (1.11 to 1.23) 2.72 (2.32 to 3.20) 2.02 (1.68 to 2.44) 2.75 (1.67 to 4.53) 0.73 (0.41 to 1.32)
CKD stage
No CKD (≥60) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Stage 3a (45–59) 1.00 (0.96 to 1.04) 1.00 (0.96 to 1.04) 0.62 (0.53 to 0.73) 0.60 (0.51 to 0.70) 2.48 (1.66 to 3.71) 2.06 (1.36 to 3.11)
Stage 3b (30–44) 0.99 (0.93 to 1.06) 1.01 (0.94 to 1.08) 1.01 (0.82 to 1.24) 0.88 (0.71 to 1.09) 7.51 (4.75 to 11.9) 5.10 (3.16 to 8.22)
Stage 4 (15–29) 1.42 (1.21 to 1.67) 1.41 (1.20 to 1.66) 2.16 (1.52 to 3.05) 1.72 (1.18 to 2.51) 24.0 (13.5 to 42.6) 11.4 (6.07 to 21.4)
Comorbidities*
Heart failure 1.15 (1.09 to 1.23) 1.16 (1.08 to 1.23) 4.00 (3.49 to 4.58) 2.93 (2.51 to 3.42) 2.90 (1.90 to 4.42) 2.22 (1.38 to 3.58)
MI 0.80 (0.75 to 0.85) 0.77 (0.72 to 0.82) 2.33 (1.98 to 2.74) 1.57 (1.32 to 1.87) 2.12 (1.33 to 3.39) 1.35 (0.80 to 2.25)
Hypertension 1.00 (0.97 to 1.02) 1.05 (1.00 to 1.11) 0.62 (0.56 to 0.68) 1.58 (1.36 to 1.84) 0.60 (0.45 to 0.80) 1.02 (0.63 to 1.65)
PAD 1.09 (1.01 to 1.18) 1.11 (1.02 to 1.20) 2.10 (1.70 to 2.60) 1.87 (1.50 to 2.33) 2.14 (1.18 to 3.86) 1.53 (0.82 to 2.88)
Arrhythmia 1.09 (1.03 to 1.14) 0.98 (0.95 to 1.01) 2.37 (2.07 to 2.71) 0.77 (0.69 to 0.86) 1.41 (0.90 to 2.21) 0.77 (0.56 to 1.05)
Diabetes mellitus 0.93 (0.90 to 0.96) 0.93 (0.90 to 0.96) 1.09 (0.97 to 1.22) 1.04 (0.92 to 1.18) 0.97 (0.69 to 1.36) 0.90 (0.63 to 1.29)
Baseline K>5 mmol/L 1.04 (1.00 to 1.10) 1.04 (0.99 to 1.09) 1.04 (0.86 to 1.25) 0.97 (0.80 to 1.17) 8.22 (6.14 to 11.0) 6.68 (4.94 to 9.02)
*The increase was based on the difference between the most recent baseline measurements within 12 months before and first follow-up measurement within 2 months after drug initiation. All
analyses were restricted to those with both baseline and follow-up measurements (n=105 859).
†Adjusted for sex, age, CKD, heart failure, MI, hypertension, PAD, arrhythmia, diabetes and calendar period of prescription start.
CKD, chronic kidney disease; K, potassium; MI, myocardial infarction; PAD, peripheral arterial disease.
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other characteristics in a multivariable analysis (table 5),
we found an increased OR for women (1.6-fold
increased), for age above 70 years (at least 1.3-fold
increased), for CKD stage 4 (1.6-fold increased), heart
failure (2.9-fold increased), peripheral arterial disease
(1.9-fold increased), myocardial infarction (1.6-fold
increased) and hypertension (1.6-fold increased).
Patients at high risk for potassium >6 mmol/L
Baseline potassium level and CKD stage, but not age
and sex, were associated with potassium levels >6 mmol/
L after ACEI/ARB initiation. Thus, the OR was seven-
fold increased for baseline potassium >5 mmol/L,
twofold increased for CKD stage 3a, ﬁvefold increased
for stage 3b, and 11-fold increased for stage 4 (table 5).
Among cardiovascular comorbidities, heart failure was
associated with the strongest OR of a potassium level
>6 mmol/L (2.22, 95% CI 1.38 to 3.58).
Monitoring high-risk patients
Some characteristics associated with increased odds of
having ≥30% rise in creatinine were also associated with
a greater likelihood of having a follow-up test within
2 weeks following drug initiation. These included older
age: persons aged 70 years or above compared with
≤50 years (1.18, 95% CI 1.13 to 1.23 for 70–79 years and
1.17, 95% CI 1.11 to 1.23 for 80+ years), CKD stage 4
compared with no CKD (1.41, 95% CI 1.20 to 1.66),
heart failure (1.16, 95% CI 1.08 to 1.23) and peripheral
arterial disease (1.11, 95% CI 1.02 to 1.20). However,
other characteristics associated with increased odds of
having ≥30% rise in creatinine were not associated with
a greater likelihood of having a follow-up test within
2 weeks following drug initiation: there was no substan-
tially increased OR (>10%) associated with female sex
(1.07, 95% CI 1.04 to 1.09), prior history of myocardial
infarction (0.77, 95% CI 0.72 to 0.82), hypertension
(1.05, 95% CI 1.00 to 1.11) or baseline potassium
>5 mmol/L (1.04, 95% CI 0.99 to 1.09). When we
excluded patients with a recent hospital admission, the
reduced OR for myocardial infarction was no longer
observed (0.93, 95% CI 0.80 to 1.08) (eTable 6). Finally,
the results remained consistent when we omitted adjust-
ment for baseline potassium (data not shown) and when
we adjusted additionally for ethnicity (eTable 6).
DISCUSSION
Only one-tenth of patients initiating ACEI/ARBs in UK
primary care appear to receive the guideline-
recommended creatinine monitoring. One in 15 patients
started ACEI/ARBs despite baseline potassium above the
recommended level, which was also shown to be a strong
predictor for severe postinitiation hyperkalaemia.
Among monitored patients, a creatinine increase ≥30%
or a potassium level >6 mmol/L occurred in almost 1.5%
of patients, and most did not discontinue therapy despite
guideline recommendations to stop. Although patients
with prior myocardial infarction, hypertension or a high
baseline potassium level were at higher risk of sudden
decline in kidney function after ACEI/ARB initiation,
there was no evidence that these patient groups were
monitored more frequently while initiating the drugs.
Strengths and limitations
Several issues should be considered when interpreting
our study results. Its large sample size increased preci-
sion. Use of the CPRD ensured that the study was
general practice-based and not restricted to speciﬁc
demographic, hospital or insurance groups.
Over the time course of this study, multiple factors
have impacted on the prescribing of ACEI/ARB and
measurement of renal function in primary care, for
example, the introduction of the relevant NICE guide-
lines, and QOF reimbursement for testing in certain
subgroups. We also did not have information about clini-
cal initiatives such as heart failure nurses and ACEI/
ARB stopping rules (‘sick-day rules’). While our main
results provide summary measures over a 10-year period,
sensitivity analyses conﬁrm that despite these changes,
the proportion receiving the guideline suggested that
biochemical monitoring does not vary during the study
period. We did not have access to blood tests performed
in hospital systems, which may have been reported to
GPs, but not recorded in CPRD. However, restricting the
analysis to patients with no recent hospital admissions
who were most likely to have had renal function mea-
sured and acted on in secondary care had little effect on
our ﬁndings. We did not examine testing during initi-
ation of dual blockade with ACEI and ARB as this com-
bination is now used very infrequently for patients with
severe comorbidities who are likely to be monitored in
secondary care. Although some patients may also have
been seen in outpatient specialty clinics, it is common
practice for specialists to ask GPs to initiate new drugs
such as ACEI/ARBs, with local biochemical monitoring,
limiting misclassiﬁcation.
Consistent with ﬁndings from other studies,19 we
found that ∼50% of all ACEI/ARB initiators were moni-
tored both before and after treatment start. If GPs are
retesting renal function in patients at higher risk of sub-
stantial biochemical changes, we may have overestimated
the proportion of patients with high potassium levels or
creatinine increases compared with the untested lower-
risk general population.
GP system software is used for issuing prescriptions,
ensuring the accuracy of prescription data. However, it
cannot be inferred that all patients actually redeemed
their prescription at the pharmacy and started medica-
tion on the same day that it was prescribed.18 20
Similarly, the estimated coverage of prescriptions may
not be completely accurate due to such factors as stock-
piling and irregular use. We also do not know whether
GPs contacted patients with elevated laboratory results
to advise them to stop taking the medication prior to
the end of their prescriptions. However, 80% of patients
Schmidt M, et al. BMJ Open 2017;7:e012818. doi:10.1136/bmjopen-2016-012818 7
Open Access
who developed creatinine increase ≥30% after ACEI/
ARB initiation were still issued a subsequent ACEI/ARB
prescription.
We aimed to detect discontinuation related closely in
time to the ﬁrst follow-up monitoring and hence most
likely resulting from an elevated creatinine or potas-
sium result. We therefore deﬁned continuation as
ACEI/ARB use beyond 30 days (the median prescrip-
tion duration) after the monitoring date. Extending
the deﬁnition of continuous use beyond 90 days
reduced the risk of misclassifying patients as continuing
treatment when they had in fact stopped. However,
extending the duration also increased the risk of identi-
fying discontinuation due to other reasons than creatin-
ine/potassium increase, for example, death or cough.
Diagnoses recorded in the CPRD generally have been
found to have adequate validity for research pur-
poses,21 22 particularly in the domains assessed by the
QOF.23 24
In the logistic regression analysis to estimate factors
associated with creatinine increase ≥30%, we excluded
patients without pre and post measurements (complete
case analysis). If the recording of creatinine levels was
not missing completely at random, the associations
between patient characteristics and creatinine increase
may have been underestimated.25 While this assumption
could not be tested directly, examination of baseline
characteristics revealed no major differences in age, sex,
socioeconomic status, and lifestyle between patients with
and without premonitoring and postmonitoring.
Furthermore, the results were consistent for each indi-
vidual patient group examined. Patients with no testing
before or after treatment initiation (including those with
potentially haemolysed samples) only accounted for
10% of all ACEI/ARB initiators.
Comparison with other studies
To the best of our knowledge, this is the largest study
conducted until now on adherence to monitoring and
discontinuation guidelines after ACEI/ARB initiation.
Only one previous study19 examined monitoring accord-
ing to guideline-recommended intervals (<14 days). All
others have used longer intervals (eg, 30 days26 or 6
months27 28), which make interpretations and implica-
tions for clinical practice less clear. Poor adherence to
monitoring guidelines after ACEI/ARB initiation is not
restricted to the UK,19 28 29 but has also been reported
in the USA,30–32 Canada33 and the Netherlands.26 34
Owing to our sample size, we were able to show that the
lack of monitoring occurred in all patient groups with
an indication for ACEI/ARB therapy.
A recent Dutch study, including 3353 patients initiat-
ing ACEI/ARBs between 2005 and 2011, found that
19% had creatinine measured within 30 days and 66%
within 1 year.26 Creatinine increases above 30% occurred
in 1.6% of patients, and among these 70% did not dis-
continue treatment.26 A Scottish study of 4056 patients
with type 2 diabetes, prescribed an ACEI/ARB between
2005 and 2009, found that 19% had both a baseline
(within 90 days) and follow-up measurement (within
2 weeks) of initiation. Within this cohort, 1.7% had both
a creatinine increase of ≥30% and potassium level
≥5.6 mmol/L.
The magnitude of the risk of severe renal impairment,
as measured by creatinine increase in these observa-
tional studies, was consistent with our ﬁndings, but
substantially higher than reported in clinical trials
(eg, 0.2% in the Ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint Trial
(ONTARGET)).35 It is not clear from the literature how
often harm occurs around the time of initiation, when
the risk of nephrotoxicity is thought to be greatest.8 If
physicians are to understand why follow-up monitoring
within 2 weeks of treatment start matters, the short-term
risks need to be clariﬁed. Until now, most studies have
reported only on cumulative risk over entire courses of
treatment, such as the 1.1% 2-year risk for potassium of
>6 mmol/L in the Studies of Left Ventricular
Dysfunction (SOLVD) trials of patients with heart
failure.36 In contrast to clinical trial reviews, reporting a
0.2% (3/1818) risk of potassium >6 mmol/L, we found a
0.4% risk of hyperkalaemia already at the time of ﬁrst
retesting after ACEI initiation.
Extending the previous literature, our results support
that advanced age, advanced CKD and heart failure, but
not sex, increase the likelihood of being moni-
tored.19 26 30 Consistent with some,26 30 but not all, previ-
ous studies,28 we found no association for diabetes.
However, these previous studies reporting an association
for diabetes focused on monitoring within broader inter-
vals (eg, 6 months),28 where patients with diabetes, irre-
spective of ACEI/ARB initiation, were likely to receive
blood testing owing to the diabetes QOF programme.
Determinants of increases in creatinine levels after
ACEI/ARB initiation are less well understood than for
hyperkalaemia, but increasing age is a consistently
reported factor.19 Advanced CKD and a range of cardio-
vascular comorbidities (mostly associated with athero-
sclerosis) were also important determinants in our
patient cohort. Consistent with previous studies, we
found that the risk of hyperkalaemia was associated with
CKD (most likely due to the impaired ability of the cor-
tical collecting tubule to secrete potassium), heart
failure (most likely due to the decreased delivery of
sodium to the distal nephron), and high pretreatment
potassium levels.6 8 19 37 We did not observe an associ-
ation with diabetes or increasing age, as could have
been expected due to diabetic nephropathy or age-
dependent hyporeninaemic hypoaldosteronism.6
Clinical relevance
Several possible explanations exist for the divergence
between the clinical guideline recommendations and
the observed monitoring and response patterns in
clinical practice. The ﬁrst is clinician non-adherence to
ordering tests. This may be due to inconsistent
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recommendations for timing and frequency of monitor-
ing over time,6 consensus-based (rather than evidence-
based) monitoring guidelines, and a lack of guidelines
tailored to particular high-risk patients, such as those
with CKD and heart failure. Although we found that
follow-up monitoring correlated well with the risk of
renal impairment after ACEI/ARB initiation for most
patient groups, it was not observed for patients with
myocardial infarction or preinitiation high potassium.
The second explanation may be patient non-adherence to
ordered tests. This is particularly salient in UK primary
care where blood samples may be taken in phlebotomy
clinics that the patient has to visit rather than the GP
practice. Patients may ﬁnd it burdensome to have blood
tests, and GPs have no direct economic incentives to
ensure that they are done. A third barrier is lack of evi-
dence of the clinical importance of monitoring and its cost-
effectiveness. ACEI/ARB-induced renal impairment is
rare in clinical trials, even among patients with multiple
risk factors for atherosclerotic renal artery stenosis.8 38
Trial results may therefore have led to a general percep-
tion that the rarity of renal impairment obviates the
need for close monitoring. However, as observed in our
data, the risks in real-world practice may be somewhat
higher and non-negligible. In addition, previous
research has shown that potassium monitoring in high-
risk patients with CKD and diabetes may reduce serious
hyperkalaemia-associated adverse events.39 Still, the
extent to which an initial creatinine increase ≥30%
translates into adverse long-term outcomes in real-world
patients remains to be clariﬁed in future studies.
Generalisability, implications and conclusions
The majority of patients initiating treatment with ACEI/
ARBs experience only minor changes in renal function.
However, substantial increases in creatinine levels after
ACEI/ARB initiation may not be as rare as previously
suggested, reinforcing the need for adherence to clinical
guidelines for both pre-initiating and post-initiating
monitoring. Moreover, the postinitiation creatinine
increase and potassium levels used in this study are
widely recognised cut-off levels, making the results inter-
nationally applicable. The comparison with the previous
literature also conﬁrms that the lack of systematic moni-
toring is not exclusive to the UK. Of particular concern
was that even when appropriate monitoring was per-
formed, severe renal impairment only rarely led to treat-
ment discontinuation. Individual patient counselling
may also be helpful to ensure that those at highest risk
are closely monitored. More work is needed to deter-
mine the prognostic importance of the changes in renal
function that we have observed.
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